Myriad Genetics shifts commercial lead, reaffirms 2026 view
Myriad Genetics replaces its chief commercial leader with an internal promotion while reaffirming previously issued full-year 2026 financial guidance.
Rhea-AI Filing Summary
Myriad Genetics, Inc. (MYGN) reported leadership changes in its commercial organization and reaffirmed its previously announced 2026 financial guidance. Effective September 16, 2026, Brian Donnelly ceased serving as Chief Commercial Officer and is expected to remain as a non-executive employee through September 21, 2026 to help transition his responsibilities.
The board appointed Vishal Sikri, formerly Senior Vice President, Product, as Executive Vice President, Commercial, effective September 16, 2026. Myriad highlighted Sikri’s molecular diagnostics and oncology experience and stated that it is reaffirming its full-year 2026 financial guidance announced on July 30, 2026.
Positive
- Reaffirmed 2026 financial guidance, confirming expectations outlined on July 30, 2026 for the full year.
- Promoted an internal leader, Vishal Sikri, with domain and commercial experience to Executive Vice President, Commercial.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Effective date of Donnelly role change: September 16, 2026
End of Donnelly transition period: September 21, 2026
Effective date of Sikri promotion: September 16, 2026
+3 more
6 metrics
Effective date of Donnelly role change
September 16, 2026
Date Brian Donnelly ceased serving as Chief Commercial Officer
End of Donnelly transition period
September 21, 2026
Expected last day as non-executive employee assisting transition
Effective date of Sikri promotion
September 16, 2026
Vishal Sikri becomes Executive Vice President, Commercial
Prior role duration for Sikri
1 year
Time serving as Senior Vice President, Product at Myriad
Guidance period reaffirmed
Full-year 2026
Financial guidance reaffirmed from July 30, 2026 earnings call
Start of Donnelly’s tenure as CCO
May 2025
Month and year he began serving as Chief Commercial Officer
Key Terms
Regulation FD Disclosure, forward-looking statements, financial guidance, molecular diagnostic testing, +1 more
5 terms
Regulation FD Disclosure regulatory
"ITEM 7.01 Regulation FD Disclosure A copy of the press release"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
financial guidance financial
"The company is reaffirming its financial guidance for the full-year 2026"
Financial guidance is the information that a company provides about its expected future financial performance, such as sales, profits, or expenses. It helps investors understand what the company aims to achieve and plan their decisions accordingly, much like a forecast or a roadmap that indicates the company's future direction. This guidance influences investor confidence and decision-making, as it offers insight into the company's outlook and growth expectations.
molecular diagnostic testing medical
"a leader in molecular diagnostic testing and precision medicine"
Molecular diagnostic testing uses tools that read the genetic material or specific molecules from a tissue, blood, or swab sample to detect disease, identify pathogens, or predict how a patient will respond to treatment. Think of it like a highly detailed fingerprint check for the biology of an illness. Investors care because these tests drive sales, regulatory scrutiny, and reimbursement decisions, so accuracy, adoption, and approval directly affect a company’s revenue and growth prospects.
precision medicine medical
"a leader in molecular diagnostic testing and precision medicine"
Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did MYGN announce on September 16, 2026?
Myriad Genetics announced that Brian Donnelly no longer serves as Chief Commercial Officer effective September 16, 2026, and that he is expected to remain as a non-executive employee through September 21, 2026 to assist with the transition of his responsibilities.
Who is Myriad Genetics’ new Executive Vice President, Commercial, and when is it effective?
Myriad Genetics appointed Vishal Sikri, formerly Senior Vice President, Product, as Executive Vice President, Commercial, effective September 16, 2026. The company announced his promotion via press release furnished as Exhibit 99.1.
What is Brian Donnelly’s transition plan at MYGN?
Brian Donnelly stopped serving as Chief Commercial Officer on September 16, 2026 and is expected to remain as a non-executive employee through September 21, 2026 to help transition his responsibilities.
Did Myriad Genetics (MYGN) change its financial guidance in this 8-K?
No. The company stated it is reaffirming its financial guidance for full-year 2026, as announced during its second quarter 2026 earnings call on July 30, 2026.
What experience does Vishal Sikri bring to his new role at MYGN?
Myriad noted that Vishal Sikri has a deep understanding of molecular diagnostics and oncology and extensive business and commercial leadership experience from prior roles, and has served as the company’s SVP of Product for the past year.
What was furnished as Exhibit 99.1 in Myriad Genetics’ 8-K?
Exhibit 99.1 is a press release dated September 16, 2026 announcing Brian Donnelly’s departure from the Chief Commercial Officer role and the promotion of Vishal Sikri to Executive Vice President, Commercial.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 15, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801 ) 584-3600
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On September 16, 2026, Myriad Genetics, Inc. (the “Company”) announced that, effective September 16, 2026, Brian Donnelly no longer serves as Chief Commercial Officer of the Company. Mr. Donnelly is expected to remain as a non-executive employee of the Company through September 21, 2026 to assist in the transition of his responsibilities.
On September 15, 2026, the Company’s Board of Directors (the “Board”) appointed Vishal Sikri, currently serving as the Company’s Senior Vice President, Product, as the Company’s Executive Vice President, Commercial, effective September 16, 2026. Mr. Sikri’s appointment as Executive Vice President, Commercial, was announced by the Company via press release on September 16, 2026.
ITEM 7.01 Regulation FD Disclosure
A copy of the press release announcing Mr. Donnelly’s departure and Mr. Sikri’s appointment as Executive Vice President, Commercial, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
| Exhibit Number | Description | |||||||
| 99.1 | Press Release dated September 16, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
Limitation on Incorporation by Reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MYRIAD GENETICS, INC. | ||||||||
| Date: September 16, 2026 | By: | /s/ Benjamin R. Wheeler | ||||||
| Benjamin R. Wheeler | ||||||||
| Chief Financial Officer | ||||||||
Exhibit 99.1
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
SALT LAKE CITY, September 16, 2026 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026.
Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles at other notable companies.
Brian Donnelly, who has served as Chief Commercial Officer since May of 2025, will be departing Myriad on September 21, 2026.
“I want to thank Brian for his contributions to Myriad,” said Sam Raha, President and CEO of Myriad Genetics. “We are excited to have Vishal lead our commercial organization. His deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of our cancer care continuum focus and profitable growth strategy going forward.”
“I’m energized to lead the commercial organization at this important stage for Myriad,” said Mr. Sikri. “I look forward to partnering with Sam and the executive leadership team to advance Myriad’s mission, serve more patients and healthcare providers, and create increased value for shareholders.”
The company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call on July 30, 2026.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call, and Mr. Sikri’s deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of the company’s Cancer Care Continuum focus and profitable growth strategy going forward. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Andria Rosell
(385) 202-3510
PR@myriad.com
(385) 202-3510
PR@myriad.com